2-aminoaryloxazole compounds as tyrosine kinase inhibitors
US7718676B2 · kind B2 · utility
29Cited by
4References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 22, 2004 |
| Grant date | May 18, 2010 |
| Priority date | — |
| Expiry date | Nov 25, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.